Navigation Links
Roche Statement Regarding Tamiflu U.S. Label Revision
Date:3/4/2008

NUTLEY, N.J., March 4 /PRNewswire/ -- Roche has informed healthcare professionals that the prescribing information for Tamiflu (oseltamivir phosphate) has been updated to reflect recommendations made by the FDA Pediatric Advisory Committee at a November 27, 2007 meeting regarding neuropsychiatric events. The revision is an update to a label change made in November of 2006 and includes information that influenza itself has been associated with a variety of neuropsychiatric events and that these reports appear to be uncommon.

The changes to the label reflect observations from a growing body of data, which shows no evidence of a causal relationship between Tamiflu and the reported events. The data shows that these neuropsychiatric adverse events also occurred in flu patients who were not taking Tamiflu. In fact, emerging evidence suggests that influenza itself may cause neuropsychiatric adverse events. In addition to clinical trials conducted prior to the approval of Tamiflu by the FDA, extensive post-marketing studies have been conducted and additional research is underway by Roche, Chugai and the Japanese health authority.

Roche agrees that it is important that healthcare professionals and patients know that all children with flu should be monitored, regardless of whether they are taking an antiviral medication. If any sign of unusual behavior is observed, a healthcare professional should be contacted immediately.

Antivirals like Tamiflu play an important role in the prevention and treatment of influenza. Tamiflu has been used by more than 48 million people worldwide, including nearly 21 million children, since its approval in 1999. Tamiflu is approved for the treatment and prevention of influenza in patients over one year of age and is one of two antiviral medications recommended by the CDC for the 2007-2008 influenza season.

Roche is committed to ensuring safe and appropriate use of our medications and will continue to conduct app
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Neurochem announces departure of two members of management team
2. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
3. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
4. Roche Completes Tender Offer for Ventana Shares
5. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
6. Roche Purchases Shares in Tender Offer for Ventana
7. Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger
8. Roche Plans to Complete Ventana Offer on February 7th
9. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
10. Rochester Medical Announces First Quarter 2008 Earnings Conference Call February 4, 2008
11. Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... Council scientists and their partners have found that their ... the transmission of multiple sexually transmitted infections (STIs) in ... simplex virus 2 (HSV-2), and human papillomavirus (HPV). The ... gel is effective against multiple strains of HIV, and ... all three viruses of at least eight hours prior ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... D.C. -- The world is less than 40 years ... implications for people and governments, according to a top ... the first time in human history, food production will ... of land, water and energy," said Dr. Fred Davies, ... security. "Food issues could become as politically destabilizing by ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Food shortages could be most critical world issue by mid-century 2
... by the Dana-Farber Cancer Institute shows more than half ... developing treatment-related infertility problems.// ,Nearly 700 members ... were 40 years old or younger were surveyed. More ... they were concerned about being infertile as a result ...
... by nurses and dieticians have been found effective in ... shown they work only when these health professionals are ... at a program in which patients received their medications ... and dieticians on factors aimed at improving their cardiovascular ...
... therapeutic option for patients with complicated type 1 diabetes, ... // Now, a new study finds ... worse survival than patients on the transplant waiting list ... Association supports a pancreatic transplant for patients who have ...
... have identified a molecule that may help older people ... cells, called satellite cells, that line the outside of ... to form new muscle tissue. They also generate new ... cells respond when a certain protein called Notch is ...
... reports, patients who were treated for depression responded better ... in their blood.// ,An increasing amount of research ... depression, but the specifics have not been understood. Researchers ... vitamin B12 and the treatment of depression. ,The ...
... suggests a common antipsychotic drug might have caused a pulmonary ... pulmonary embolism results when a blood clot that developed elsewhere ... be deadly. Antipsychotic drugs have been linked to an increased ... shown an association between blood clots and the drug clozapine. ...
Cached Medicine News:Health News:Pancreas Transplant for Diabetics 2
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 2 data continue to show encouraging anti-tumor activity in,non- small cell ... ... XL647 administration, SAN FRANCISCO, Oct. 24 Exelixis, Inc.,(Nasdaq: ... study of XL647,an inhibitor of EGFR, HER2 and VEGFR kinases, in ...
... Clinical Studies TAX 323 and TAX 324 Published, ... that results of two clinical studies demonstrating that,Taxotere(R) ... fluorouracil for induction therapy, significantly improved overall,survival (OS) ... of,the head and neck (SCCHN) are published in ...
Cached Medicine Technology:Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 2Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 3Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 4Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 2Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 3Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 4Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 5Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 6Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine 7
... Exceptional comfort for those with ... Toric soft contact lenses let you enjoy ... other soft toric lensa difference youll especially ... throughout the day., This exceptional level of ...
Frequency 55 Toric monthly soft toric lenses....
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Medicine Products: